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Abstract Patients with peripheral artery disease are at high
risk of coronary artery disease. An increasing number of
studies show that a large proportion of patients with peripheral
artery disease have significant coronary atherosclerosis, even
in the absence of symptoms. Although the reported prevalence
of subclinical coronary artery disease varies widely in patients
with peripheral artery disease, it could include more than half
of patients. No consensus exists to date on either the rationale
for screening patients with peripheral artery disease for coro-
nary atherosclerosis or the optimal algorithm and method for
screening. An increasing number of imaging modalities are
emerging that allow improved in vivo non-invasive character-
ization of atherosclerotic plaques. These novel imaging
methods may lead to early detection of high-risk vulnerable
plaques, enabling clinicians to improve risk stratification of
patients with peripheral artery disease, and thus paving the
way for individualized therapy.
Keywords Atherosclerosis . Imaging . Peripheral artery
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Introduction
Atherosclerosis is a systemic degenerative inflammatory vas-
cular disease and the primary underlying cause of coronary
heart disease. Atherosclerosis develops over decades, with a
long subclinical period. About half of all patients who die from
coronary heart disease have no prior diagnosis or symptoms of
cardiac disease [1]. Despite this fact, screening asymptomatic
adults for cardiovascular risk by imaging is considered inap-
propriate in most cases by current guidelines [2].
Clinical risk stratification of asymptomatic patients is typi-
cally performed using global risk scores such as the Framing-
ham risk score or HeartScore, rendering a 10-year risk of car-
diovascular death on the basis of “classic” cardiovascular risk
factors. In addition to the clinical risk scores, a number of
medical conditions indicate a cardiovascular risk similar to that
of patients with established coronary heart disease [3••, 4]. These
coronary heart disease risk equivalents are conditions such as
diabetes and peripheral artery diseases (PAD), including lower
limb arterial disease, abdominal aortic aneurism, and carotid
artery disease. Given the high cardiac mortality and morbidity,
early detection and treatment of subclinical coronary heart dis-
ease could potentially improve prognosis in patients with PAD.
This article will address the use of imaging methods for
identification of subclinical coronary artery disease in patients
with known PAD and will discuss the indications for imaging
for subclinical coronary artery disease, both with regard to
general screening and in the subgroup of patients with PAD
who are referred for major surgery.
Prevalence of Subclinical Coronary Artery Disease
in Patients with PAD
More than 30 years ago, Hertzer et al. established that patients
undergoing surgical management of PAD had a high
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prevalence of significant coronary artery disease and that a
large proportion of the patients were asymptomatic [5]. It is
now well documented that patients with atherosclerosis in
major peripheral arteries also have a high risk of myocardial
infarction [6].
A positive association between carotid and coronary ath-
erosclerosis has been recognized for decades [7]. In the
AMISTAD study of 405 patients with acute cerebral infarction
[8], 85%who underwent coronary angiography had no known
coronary artery disease. Coronary plaques were found in 62%
and coronary stenoses (≥50%) in 26% of the asymptomatic
patients. In addition, the burden of systemic atherosclerosis
was determined by ultrasound examination of the carotid
arteries, the aorta, and the femoral artery. After adjustment
for traditional risk factors, the presence of coronary plaques
was significantly associated with the presence of plaques in
the carotid and femoral arteries. As was previously suggested
by the REACH registry [9], polyvascular disease increased the
risk of coronary plaques. In a recent report on clinical follow-
up from the AMISTAD study [10•] both the presence and
extent of coronary atherosclerosis were found to predict major
vascular events in the 2-year follow-up period.
The prevalence of subclinical coronary artery disease re-
ported in the AMISTAD study is supported by both the
PRECORIS study [11] and autopsy studies following fatal
stroke [12]. However, a limitation present in both AMISTAD
and PRECORIS was the fact that patients were stratified
according to known coronary disease (acute coronary syn-
drome,myocardial infarction, or revascularization), and thus it
must be considered that some of these patients could be
symptomatic (e.g., having mild angina or angina equivalents)
though undiagnosed. If this is the case, one would expect that
the prevalence of true subclinical coronary disease is
overstated in these trials. Conversely, in a study of 420 pa-
tients with significant carotid stenosis, Hofmann et al. [13]
found that approximately 60% of patients without cardiac
symptoms had significant coronary stenoses as demonstrated
by coronary angiography. It can be speculated that this ob-
served difference in subclinical coronary artery disease is
attributable to the differences in the cohorts studied (stroke
vs. significant carotid stenosis).
A recent review of the literature including 1,277 patients
reported that 50% of patients with abdominal aortic aneurisms
had significant coronary artery disease [14]. This number
should be regarded with caution, however, as the studies are
heterogeneous with regard to inclusion criteria and methods
and span more than four decades. Most of the studies included
patients both with and without symptoms of myocardial is-
chemia. Only two studies specified the prevalence of true
subclinical coronary artery disease in patients with abdominal
aortic aneurism. Quigley and colleagues reported that 33% of
102 asymptomatic patients scheduled for surgical repair and
screened by myocardial scintigraphy and/or by invasive
angiography were found to have significant coronary artery
disease [15]. Similarly, Kioka et al. found that 36% of asymp-
tomatic patients with PAD had significant coronary stenosis
(≥75%) by coronary angiography [16].
Patients with lower limb arterial disease are at increased
risk of mortality from cardiovascular and coronary heart dis-
ease, even if PAD is asymptomatic [17]. Only a few studies
have investigated subclinical coronary disease in patients with
lower limb PAD. Her et al. performed coronary angiography
prior to peripheral vascular surgery in 82 patients without
symptoms of coronary heart disease and found that 70% had
coronary atherosclerosis and 33% had ≥70% coronary steno-
sis [18]. In comparison, Hirose et al. performed stress-rest
myocardial perfusion imaging in 183 patients with lower limb
PAD and found significant presence of ischemia in 55% of the
patients [19]. As some patients were reported to have angina
pectoris, a direct comparison of the two studies is difficult.
One very recent study included 200 patients with symptomatic
lower limb PAD but without angina, dyspnea, or known
coronary artery disease [20••]. Invasive angiography was per-
formed in all patients and showed coronary atherosclerosis in
68%, with significant (≥70%) coronary stenosis in 55%.
In summary, the reported prevalence of subclinical cor-
onary artery disease in patients with PAD varies widely
(Tables 1). This may be attributable, at least in part, to a
number of methodological differences. First, the definition
of coronary symptoms is variable. For example, should
dyspnea, syncope, or an abnormal ECG be designated as
coronary symptoms? In addition, lower limb arterial dis-
ease may mask coronary ischemia as a result of functional
limitations from the PAD. Second, the prevalence seems to
vary according to the location of the PAD. Third, the accu-
racy of the screening method for coronary artery disease
will affect the prevalence. Despite differences in reported
prevalence, it is clear from all reported series that patients
with PAD have a significantly increased prevalence of
subclinical coronary artery disease and a high risk of sub-
sequent complications.
Rationale for Screening for Subclinical Coronary Artery
Disease in PAD
Screening for coronary artery disease (CAD) in patients with
PAD remains a controversial subject, both in the general PAD
population and for selected subgroups, and particularly in
PAD patients referred for major surgery.
In patients with PAD who are referred for major surgery,
whether for the PAD itself or for other diseases, the risk of
postoperative cardiac morbidity and mortality is significantly
higher, and preoperative screening for significant CAD is
often recommended [21]. However, there is little evidence
that supports screening for coronary disease and possible
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interventions as a means of reducing cardiac complications
[21].
One recent study included 208 patients with PAD sched-
uled for major elective vascular surgery with a revised cardiac
risk index ≥2 [22]. Patients were randomized to coronary
angiography followed by extensive revascularization or to
coronary angiography based on the result of ischemia testing
(stress-echocardiography or stress-thallium scintigraphy). Re-
vascularization was performed in 61 patients in the first group
and 42 in the second group. On follow-up, patients random-
ized to routine coronary angiography showed better survival
and freedom from death/cardiovascular events [22]. Unfortu-
nately, this study did not specify whether any of these patients
were without symptoms of myocardial ischemia. Additional-
ly, the study compared two different imaging-derived strate-
gies only. It would have been of interest also to compare to a
group treated conservatively with only medication and life-
style modification but without revascularization.
In the CARP trial, McFalls et al. had determined that
revascularization before vascular surgery did not alter long-
term outcome when compared to patients randomized to no
revascularization [23]. This study included a highly selected
cohort of PAD patients with stable cardiac symptoms and
coronary angiography showing a significant stenosis. The
results supported the contention that many acute cardiovascu-
lar events originate from stenoses that are without hemody-
namic significance. A new analysis from the CARP trial
further demonstrated that only patients with unprotected left
main coronary artery disease had a prognostic benefit from
preoperative coronary artery revascularization [24].
Patients with stroke are known to have high cardiovascular
risk, even with optimal secondary therapy [10•]. One trial
investigated the use of systematic preoperative coronary an-
giography, followed by percutaneous coronary intervention,
before carotid endarterectomy in patients without clinical
evidence of CAD [25]. All patients (n=426) were without
any clinical sign or history of ischemic heart disease. Patients
were randomized to 1) angiography and percutaneous coro-
nary intervention if a significant stenosis was detected or 2) no
angiography prior to carotid endarterectomy. Systematic an-
giography was shown to significantly reduce the incidence of
postoperative myocardial events. The 30-day survival and
stroke rates were equal in the two groups [25]. Limitations
of the study included few clinical endpoints and a short
follow-up period. In addition, optimal postoperative medical
treatment was not part of the study protocol.
If a significant CAD is demonstrated in the general popula-
tion of PAD patients without coronary symptoms, should it then
lead to medical prophylactic intervention or to coronary revas-
cularization? In fact, very few studies have addressed the prog-
nostic impact of image-guided therapy in this setting. Many
will advocate that all patients with severe PAD should already
be treated to maximal secondary prevention, and that imaging
of the coronary arteries should not alter this treatment, and it is
therefore not relevant. Others will advocate that significant
coronary artery disease should lead to invasive treatment with
percutaneous coronary intervention or bypass surgery in these
asymptomatic but high-risk patients. A randomized controlled
investigation is sorely needed to address these questions.
In summary, numerous studies have identified severe sub-
clinical CAD in a substantial proportion of patients with PAD,
but a beneficial effect of general screening for CAD by either
noninvasive or invasive imaging on occurrence of coronary
events has yet to be determined. Large prospective randomized
trials are needed in order to provide clarity. As a preoperative
investigation before intermediate or high-risk cardiac surgery,
limited data suggest a beneficial effect of preoperative imaging
of the coronary vessels or myocardial perfusion distribution.
From a theoretical risk reduction perspective, a potential
benefit in both the general PAD patient population and as a
Table 1 Prevalence of subclinical coronary artery disease in patients with symptomatic peripheral artery disease
Study Year Diagnostic modality No. of
patients
Kind of
PAD
Prevalence of
coronary stenoses
Symptoms of coronary
artery disease
Hertzer et al. 1985 Coronary angiography 506 Carotid 16% No
Amarenco et al. 2011 Coronary angiography 405 Stroke 26% No known CAD
Calvet et al. 2010 CCTA 274 Stroke 18% No known CAD
Hofmann et al. 2005 Coronary angiography 420 Carotid 60% No
Hur et al. 1972-2012 Coronary angiography 1277 AAA 50% Both symptomatic and asymptomatic
Quigley FG et al. 1999 Tl-201 SPECT 102 AAA 33% No
Kioka et al. 2002 Coronary angiography 94 AAA 36% No
Her et al. 2008 Coronary angiography 82 LEAD 33% No
Hirose et al. 2009 Tl-201 SPECT 183 LEAD 55% Both symptomatic and asymptomatic
Marsico et al. 2013 Coronary angiography 200 LEAD 55% No
AAA=abdominal aortic aneurism, CCTA=coronary computed tomography angiography, CAD=coronary artery disease, LEAD=lower extremity arterial
disease, PAD=peripheral artery disease, SPECT=single photon emission tomography
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preoperative coronary imaging study of subclinical CAD may
be the identification of vulnerable plaques that are prone to
rupture or to cause thrombus that may subsequently lead to
myocardial infarction. Conceptually, this can be accomplished
by imaging the plaque, the anatomy of the coronary vessel, or
ischemia.
Non-Invasive Imaging of the Coronary Arteries
and Coronary Plaques
In addition to invasive coronary angiography, a considerable
number of noninvasive imaging modalities are available that
can suggest or demonstrate the presence of coronary artery
lesions, either by anatomical or functional or by combined
anatomical-functional information showing increased risk of
coronary events (Table 2).
Surrogate Measures of Coronary Plaques
Flow-mediated dilatation is a test to measure endothelial
dysfunction and thus a surrogate measure of coronary athero-
sclerosis. The endothelial dysfunction is measured in the
brachial artery using ultrasound. Patients with PAD are known
to manifest atherosclerosis, and as endothelial dysfunction is
an early hallmark of atherosclerosis, it should be expected that
flow-mediated dilationwould be attenuated in all patients with
PAD. This was demonstrated in a study of 44 patients with
PAD but without symptoms of coronary artery disease [26]. In
addition, the authors found that the degree of flow-mediated
dilatation could predict the presence of ischemia on myocar-
dial perfusion imaging. Thus far, these intriguing results have
not been validated by other studies.
Coronary artery calcium score (CACS) is calculated from a
non-contrast CT of the heart. CACS reflects the total plaque
burden and provides incremental prognostic information be-
yond traditional clinical risk scores (e.g., Framingham and
HeartScore) [27]. However, calcification is not a hallmark of
vulnerable plaque, and in fact is often seen in stable plaques.
CACS, therefore, likely does not image the vulnerable plaque
and should be considered a surrogate measure of all plaques,
both calcified and non-calcified. Because CACS is a fast, non-
invasive, low-cost examination, and subjects the patient to
only minimal radiation (typically around 1 mSv), it may
potentially serve as a first-line examination in order to select
asymptomatic patients with PAD who require subsequent
coronary examination. A recent report from the prospective
GROUND2 study used this approach in a cohort of 111
patents with PAD and no symptoms of cardiovascular disease
[28••]. However, only eight of the patients were found to have
0 CACS and no plaques on coronary CT. As such, CACS as a
screening method in patients with PAD would likely add very
little information, as most patients will have increased score
and will require further imaging.
An intriguing perspective of CACS is the fact that it can
reclassify risk in subsets of patients. For example, patients
Table 2 Non-invasive imaging modalities for the study of subclinical coronary artery disease in patients with peripheral artery disease
Imaging modality Advantages Drawbacks
Coronary artery calcium score Low price
High availability
Does not visualize non-calcified plaques
Low specificity in patients with PAD
Coronary angiography by CT High sensitivity for stenotic plaque
Can image plaque morphology
High availability
Ionizing radiation
Plaque imaging technically challenging
Cardiac magnetic resonance imaging Can image plaque morphology
High spatial resolution
Technically very challenging
Limited availability and high cost
Stress echocardiography High availability Does not visualize plaques
Operator-dependent
MPI with SPECT Prognostic information
Low spatial resolution
Does not image plaque
Ionizing radiation
MPI with PET Image stress induced ischemia
Limited spatial resolution
Does not visualize plaques
High cost and low availability
Ionizing radiation
FDG-PET/cardiac CT Combined anatomical and metabolic imaging High cost and limited availability
Ionizing radiation
MPI PET/cardiac CT Combined anatomical and ischemia imaging High cost and low availability
Ionizing radiation
Specific PET plaque tracer/cardiac CT Potentially specific identification of vulnerable plaque Method still at the experimental level
Ionizing radiation
MPI=myocardial perfusion imaging, PAD=peripheral artery disease, PET=positron emission tomography, SPECT=single photon emission computed
tomography
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with diabetes and 0 CACS have a cardiovascular event rate
similar to patients without diabetes, thereby challenging the
notion of diabetes as a coronary heart disease risk equivalent
per se [29]. Future studies will need to determine whether this
could also apply to patients with PAD.
Another method for imaging calcium is positron emission
tomography (PET) using 18F-labeled sodium fluoride (NaF).
This tracer is deposited by chemisorptions onto hydroxyapa-
tite and is used in oncology to identify sclerotic bone metas-
tasis. Recent evidence suggests that it is not equivalent to
CACS imaging [30] but that it can identify “spotty” calcifica-
tion in the plaques thought to promote plaque vulnerability. In
fact, results from one study indicate that NaF PETcan identify
culprit and ruptured plaques in patients with recent myocardial
infarction [31•].
Compared to both NaF and particularly CACS, it may be
more attractive to image more specific characteristics of the
vulnerable plaque.
Anatomical Coronary Plaque Imaging
Coronary angiography by CT (CCTA) is a non-invasive meth-
od using intravenous contrast, typically to assess luminal
stenoses. However, it has been shown that CCTA can also
provide images of the vessel wall, and thus plaque character-
istics, including positive remodeling, densitometry, and calci-
fication [32]. With improved resolution, even small plaques
that are not flow-limiting may potentially be assessed for
vulnerability characteristics, although the spatial resolution
remains a limitation for direct identification of vulnerable
plaques [32]. Another challenge for CCTA is the fact that
atherosclerosis is a systemic disease typically involving large
parts of the coronary arteries. A comprehensive evaluation of
coronary plaque morphology by visual evaluation is a cum-
bersome task. Multisequence magnetic resonance imaging
(MRI) is also able to image the coronary artery wall and
plaque morphology [33]., This method is even more techni-
cally challenging, however, due to cardiac and respiratory
motion of the often small tortuous vessels. MRI does appear
to be useful for imaging the larger carotid and aortic plaques.
Myocardial Ischemia Imaging
There are several methods for examining myocardial perfu-
sion, and thus ischemia. Traditionally, this is accomplished by
myocardial perfusion single-photon emission tomography
(SPECT) using an intravenous injection of 99mtechnetium-
labeled tetrofosmin or sestamibi during stress and rest. The
use of PET for perfusion imaging is growing and has several
advantages compared to SPECT: higher spatial resolution,
faster acquisition, fewer motion artifacts, and absolute flow
quantification. The perfusion tracers used for PET imaging are
82Rb, 15O-labeled water, or 13N-labeled ammonia [34]. The
primary drawbacks of PET are the limited availability of
scanners and perfusion tracers. Both CT and MRI can also
image regional myocardial perfusion by dynamic first-pass
contrast-enhanced imaging. These methods are less validated
in comparison to PET, and particularly SPECT imaging, but
the higher resolution is a potential advantage. Dobutamine
stress echocardiography combines pharmacological stress
with ultrasound imaging to identify left ventricular wall mo-
tion abnormalities within the distribution of significant stenot-
ic coronary arteries.
An important advantage of myocardial perfusion imaging
is that it is a functional method of imaging perfusion at the
myocyte level and thus can determine whether a borderline
epicardial stenosis causes a significant change in perfusion.
One study (n=111) on the association between PAD and
subclinical CAD combined anatomical (CCTA) and ischemia
(stress MRI) imaging [28••]. Of 80 patients with plaques on
the CCTA (40 with significant and 40 with non-significant
stenosis), only 10 were found to have ischemia on subsequent
stress MRI.
Perfusion imaging in asymptomatic patients with PAD is
useful for identification of areas with silent ischemia, and it is
well established that patients without inducible ischemia have
very low cardiac event rates (approximately 1% during the
following year [35]). However, patients with established PAD
will probably have a higher prevalence of non-stenotic vul-
nerable plaques that cannot be identified with myocardial
perfusion imaging, and the negative predictive value of myo-
cardial perfusion imaging in this patient population will likely
be lower, as was previously shown in diabetic patients [36].
Metabolic Imaging of the Vulnerable Plaque
PET imaging of atherosclerosis has thus far focused primarily
on fluorine-18-fluorodeoxyglucose (18F-FDG). The molecule
is a glucose analogue that accumulates in metabolically active
cells such as macrophages. The first report on 18F-FDG accu-
mulation in the large arteries emerged in 2001 [37], and since
then, a large body of evidence has materialized linking FDG
uptake to the macrophage contents of high-risk plaques
[38–40]. This observation is in line with the emerging con-
sensus of atherosclerosis as an inflammatory disease. A major
drawback of imaging coronary atherosclerosis with FDG-
PET, however, is the lack of specificity of the tracer, and
another limitation is the high uptake of FDG in the myocar-
dium, which produces a suboptimal signal-to-noise ratio.
Consequently, in contrast to FDG imaging of carotid plaques,
few studies have utilized FDG-PET to image coronary ath-
erosclerosis [41•, 42]. One recent retrospective study indicated
a potential future role of arterial FDG-PET in risk stratification
of asymptomatic patients. The authors retrospectively identi-
fied 513 FDG-PET examinations and revealed a predictive
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value of arterial FDG uptake for subsequent cardiovascular
events in asymptomatic individuals [43].
As an alternative, some researchers have suggested 18F-
deoxy-mannose (18F-FDM) as a more specific tracer than 18F-
FDG [44], but this needs to be confirmed in clinical trials. To
date, no studies have been published on the application of
coronary PET imaging in patients with PAD.
Specific PET Tracers for Plaque Imaging
New and potentially more specific PET tracers for imaging
coronary atherosclerosis are emerging [45]. The tracers spe-
cifically target the cell-mediated key molecular processes
associated with the vulnerable atherosclerotic plaque. The
most prominent of these targets include macrophage infiltra-
tion, apoptosis, hypoxia, and neoangiogenesis of the intima/
media. As discussed, FDG-PET is capable of imaging macro-
phage infiltration in the plaques but with low specificity.
Another potential target is the somatostatin receptor subtype
2 expressed by macrophages. The somatostatin receptor li-
gand 68Ga-DOTATATE has high affinity for somatostatin
receptors, and a few studies have suggested a future role in
plaque imaging [46–48]. PET tracers for imaging apoptosis,
hypoxia, and neoangiogenesis are available, but their use in
coronary artery plaque imaging is extremely limited thus
far [49•, 50, 51]. A review of new PET and SPECT tracers,
as well as tracers used in other modalities, was recently
published [52].
Hybrid Imaging
Hybrid imaging combining anatomical information from a
CCTA with metabolic or molecular information from PET
imaging may represent a valuable non-invasive modality for
the identification of significant microvascular disease and
flow-limiting epicardial coronary artery lesions, as well as
for demonstration of the characteristics of the vulnerable
plaque in selected patients with PAD.
Clinical integrated PET/MRI systems have recently been
introduced. MRI can effectively characterize plaque morphol-
ogy (e.g., hemorrhage and the lipid-rich necrotic core), and the
combination with PET-derived molecular imaging holds great
potential for in vivo identification of vulnerable plaques. The
limited availability of the PET/MRI imaging systems and
expensive production of specific PET tracers, however, will
likely restrict such a technique to experimental use for some
time. Thus far, few reports have been published on hybrid
imaging for the study of atherosclerosis [53•], and none have
used it for coronary artery imaging. One study combined
CACS with CCTA and MRI to identify high-risk PAD pa-
tients, but the image selection protocol itself was not validated
in the trial [28••].
Conclusion
An already significant and ever-increasing body of evidence
indicates a high prevalence of subclinical coronary atheroscle-
rosis in patients with manifest PAD. The value of general
screening of coronary arteries with non-invasive imaging in
patients with PAD is not documented. Limited data suggest
that imaging patients with PAD before major surgery may be
valuable. A palette of potentially specific tracers targeted
against plaque vulnerability exists via various imaging mo-
dalities including PET, CT, MRI, ultrasound, and imaging
combinations. Future studies will determine whether identifi-
cation of patients with PAD at high risk for CAD complica-
tions will eventually improve prognosis.
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